INT345169

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.08
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 2.26
Pain Relevance 0.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Lpar1) nucleus (Dmbx1) plasma membrane (Lpar1)
DNA binding (Dmbx1) cytoplasm (Lpar1) signal transducer activity (Lpar1)
Anatomy Link Frequency
plasma 1
Lpar1 (Mus musculus)
Dmbx1 (Mus musculus)
Pain Link Frequency Relevance Heat
antagonist 30 99.08 Very High Very High Very High
agonist 30 53.52 Quite High
fibrosis 18 5.00 Very Low Very Low Very Low
Neuropathic pain 16 5.00 Very Low Very Low Very Low
dorsal root ganglion 8 5.00 Very Low Very Low Very Low
Pain 8 5.00 Very Low Very Low Very Low
metalloproteinase 8 5.00 Very Low Very Low Very Low
Potency 6 5.00 Very Low Very Low Very Low
alcohol 4 5.00 Very Low Very Low Very Low
Multiple sclerosis 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Metastasis 20 96.04 Very High Very High Very High
Breast Cancer 6 95.36 Very High Very High Very High
Cancer 48 93.80 High High
Ovarian Cancer 32 92.88 High High
Skin Cancer 6 87.28 High High
Disease 14 86.76 High High
Targeted Disruption 30 83.44 Quite High
Apoptosis 30 78.76 Quite High
Pressure And Volume Under Development 4 75.32 Quite High
Hyperplasia 4 69.00 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This feedback inhibition of ATX by LPA has been proposed to be a factor in maintaining plasma levels of LPA in the low nanomolar range (van Meeteren et al., 2005).
LPA Negative_regulation (inhibition) of ATX in plasma
1) Confidence 0.08 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 1.29 Pain Relevance 0
(Zhang et al., 2009a) have developed alpha-bromophosphonate analogues of LPA that inhibit ATX activity and also are antagonists of LPA1,2,3,4,5 GPCR and showed that these dual-action compounds not only reduce breast cancer metastasis but also inhibit tumour growth.
LPA Negative_regulation (inhibit) of ATX associated with cancer, antagonist, breast cancer and metastasis
2) Confidence 0.05 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.96 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox